Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

CD INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring (INFORM)

This study has been terminated.
(Sponsor's decision.)
Information provided by (Responsible Party):
Biogen Identifier:
First received: June 27, 2008
Last updated: July 16, 2015
Last verified: June 2015
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: August 2050
  Estimated Primary Completion Date: August 2050 (Final data collection date for primary outcome measure)